Merck KGaA has updated sales expectations for its newly launched drugs in 2022, from around €2bn previously to €1.6-1.8bn, including moderating its sales ambitions for the multiple sclerosis drug Mavenclad, because of COVID-19-related effects.
Merck KGaA Moderates New Drug Sales Ambitions For 2022
Raises Financial Guidance For 2021
Merck KGaA has narrowed its 2022 sales forecasts for its newly launched pharmaceuticals because of the COVID-19 pandemic, but still expects strong growth from these products and from products and services in its process solutions and electronic businesses.
More from Neurological
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.